InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript

Group 1 - The conference call is focused on discussing the top line Phase IIa data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [1] - Niels Riedemann, CEO and Founder of InflaRx, expresses excitement about reaching this stage in the development of INF904 [1] - Dr. Camilla Chong, Chief Medical Officer, will present data specifically related to chronic spontaneous urticaria, while Niels Riedemann will present data on hidradenitis suppurativa [1] Group 2 - Professor John Ingram, a treating physician and key opinion leader in HS treatments, will participate in the Q&A session [2]